Marinomed Biotech Aktie

16,30 EUR +0,50 EUR +3,16 %

14:37:12

STU

17,50 EUR +0,50 EUR +2,94 %

16:06:30

WIEN

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.30,23 Mio. EUR

Div. Rendite0,00%

WKNA2N9MM

ISINATMARINOMED6

Marinomed Biotech Aktien News

Sortieren:Datum Meistgelesen

14.05.25EQS GroupEQS-AGM: Supplemented Version of the Convocation published on May 12, 2025 for the 8th Annual General Meeting for Wednesday, June 11, 2025 at 9:00 a.m. (Vienna time)

12.05.25EQS GroupEQS-AGM: Marinomed Biotech AG: Invitation to the 8th Annual General Meeting on Wednesday, June 11, 2025, at 09:00 (Vienna time)

08.05.25EQS GroupEQS-News: Marinomed Biotech AG announces results for the first quarter of 2025

WerbungMarinomed Biotech-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

16.04.25EQS GroupEQS-AFR: Marinomed Biotech AG: Release of a Financial report

10.04.25EQS GroupEQS-News: Marinomed Biotech AG: Launch of new moisturizing Carragelose eye drops in Austria

27.03.25EQS GroupEQS-News: Marinomed focuses on growth after successful restructuring

28.02.25EQS GroupEQS-News: Marinomed Biotech AG: Successful completion of the sale of the Carragelose business to Unither Pharmaceuticals

27.02.25EQS GroupEQS-AFR: Marinomed Biotech AG: Release of a Financial report

31.01.25EQS GroupEQS-News: Marinomed Biotech AG: Changes to the Management Board

20.01.25EQS GroupEQS-DD: Marinomed Biotech AG: Dr. Karl Mahler, buy

20.01.25EQS GroupEQS-News: Marinomed Biotech AG: Restructuring proceedings successfully completed

31.12.24EQS GroupEQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution

30.12.24EQS GroupEQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

19.12.24EQS GroupEQS-News: Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division

17.12.24EQS GroupEQS-News: Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved

05.12.24EQS GroupEQS-Adhoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share

28.11.24EQS GroupEQS-AGM: Marinomed Biotech AG: Invitation to an Extraordinary General Meeting on Thursday, December 19, 2024, at 9:00 a.m. (Vienna time)

27.11.24EQS GroupEQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed

27.11.24EQS GroupEQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares

27.11.24EQS GroupEQS-News: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals

26.11.24EQS GroupEQS-Adhoc: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals

14.11.24EQS GroupEQS-Adhoc: Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors

12.11.24EQS GroupEQS-News: Marinomed Biotech AG publishes clinical data for decongestant Carragelose nasal spray in peer-reviewed International Journal of General Medicine

24.10.24EQS GroupEQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

11.10.24EQS GroupEQS-Adhoc: Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio

08.10.24EQS GroupEQS-News: Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal

30.09.24EQS GroupEQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

30.09.24EQS GroupEQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution

26.09.24EQS GroupEQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution

24.09.24EQS GroupEQS-News: Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops

20.09.24EQS GroupEQS-DD: Marinomed Biotech AG: Simon Nebel, buy

20.09.24EQS GroupEQS-DD: Marinomed Biotech AG: Andreas Grassauer, buy

20.09.24EQS GroupEQS-DD: Marinomed Biotech AG: Eva Prieschl-Grassauer, buy

18.09.24EQS GroupEQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share

15.09.24EQS GroupEQS-Adhoc: Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights

11.09.24EQS GroupEQS-News: Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification

02.09.24EQS GroupEQS-Adhoc: Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights

Marinomed Biotech News

Marinomed Biotech News: auf dieser Seite finden Sie alle Marinomed Biotech News und Nachrichten zur Marinomed Biotech Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Marinomed Biotech News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Marinomed Biotech News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.